NCT/Study#

NCT04196491 /

BB-2121-MM-004

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, ACTIVEly Diagnosed Multiple Myeloma (KarMMa-4)

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, ACTIVEly Diagnosed Multiple Myeloma (KarMMa-4)

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: